| LBCTR2021024744 | CEUA 056 | The Effect of Rhythmic Auditory Stimulation on Gait in Chronic Stroke Patients | The Effect of Rhythmic Auditory Stimulation Tempo Shifts Application on Gait Parameters in Chronic Stroke Patients: A Pilot Study | Interventional | Recruiting | 14/02/2021 |
| LBCTR2022095130 | CEHDF2040 | Ergonomics and Mindfulness for preventing musculoskeletal pain and a better quality of life | Effect of ergonomics and mindfulness on musculoskeletal pain and quality of life for office workers: a randomized controlled trial | Interventional | Recruiting | 19/09/2022 |
| LBCTR2021054816 | CEHDF 1787 | Effects of different mental training techniques on fine motor performance. | Comparison between the effects of Neurofeedback training and Motor imagery training on motor performance in a finger tapping task. | Interventional | Recruiting | 16/06/2021 |
| LBCTR2021044784 | CBYL719H12301 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation | A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation | Interventional | Suspended | 15/04/2021 |
| LBCTR2022054889 | CBYL719G12301 | Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | EPIK-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | Interventional | Suspended | 04/11/2021 |
| LBCTR2019030190 | CBYL719C2301 | A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment | SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment | Interventional | Complete | 07/02/2019 |
| LBCTR2019020191 | CAIN457M2302 | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE) | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE) | Interventional | Complete | 08/02/2019 |
| LBCTR2020124720 | CAIN457M2301E1 | Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa | CAIN457M2301E1 A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa | Interventional | Complete | 29/12/2020 |
| LBCTR2024065610 | CAIN457C22301E1 | Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) | A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) | Interventional | Pending | 14/06/2024 |
| LBCTR2023035313 | CAIN457C22301 | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) | Interventional | Pending | 22/03/2023 |